HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Aspartoacylase deficiency and Canavan disease in Saudi Arabia.

Abstract
We found defective aspartoacylase activity in fibroblasts cultured from 12 patients with leukodystrophy clinically diagnosed as spongy degeneration of the brain (Canavan disease), three confirmed by brain biopsy. The activity of aspartoacylase ranged between 1 and 13% of two groups of control individuals, normals, and those with other leukodystrophies. The present report confirms the study of Matalon et al. [1988] in a totally different ethnic group and provides independent verification that aspartoacylase activity is the first documented specific biochemical marker in Canavan disease and plays an important role in pathogenesis. Considering that only some 75 cases had been reported up to 1982, our group of 12, accumulated within 3 years, is inordinately large and suggests that Saudi Arabia provides a promising venue in which to study the biochemical and molecular genetics of Canavan disease.
AuthorsP T Ozand, G G Gascon, M Dhalla
JournalAmerican journal of medical genetics (Am J Med Genet) Vol. 35 Issue 2 Pg. 266-8 (Feb 1990) ISSN: 0148-7299 [Print] United States
PMID2309767 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Amidohydrolases
  • aspartoacylase
Topics
  • Amidohydrolases (deficiency)
  • Blindness (etiology)
  • Brain Diseases, Metabolic (diagnosis)
  • Consanguinity
  • Dementia
  • Female
  • Humans
  • Male
  • Retrospective Studies
  • Saudi Arabia

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: